Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome ...Middle East

Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update at the FAST Global Science Summit in...

Hence then, the article about ionis announces pivotal phase 3 trial design for ion582 in angelman syndrome was published today ( Wednesday 06/11/2024 - 03:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome )

Also on site :

• Potato futures are soaring – should the world be worried?
• Ukrainian arms firm linked to graft probe says NATO member froze factory project
• Starbucks to Cut 300 Jobs— Here's How to Handle a Layoff According to a Pro